Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACT vs. STAMP V in High-Risk Primary Breast Cancer
NCT00004092Phase 2Completed
- Sponsor
- City of Hope
- Start
- May 1999
- Primary completion
- Dec 2013
- Modality
- Targeted Liposomes, Cytokines & Interferons, Stealth (PEGylated) Liposomes
- Countries
- 1
01
Overview
A Phase 2 trial of pegylated liposomal doxorubicin, cyclophosphamide, Paclitaxel Micelles for Injection in breast cancer, sponsored by City of Hope. Started May 1999; status: completed.
02
Drugs
pegylated liposomal doxorubicincyclophosphamidePaclitaxel Micelles for Injection
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00004092.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00004092.